EP
ALNY icon

Evelyn Partners’s Alnylam Pharmaceuticals ALNY Stock Holding History

Evelyn Partners’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$52.7K Buy
+175
New +$52.8K ﹤0.01% 366

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Evelyn Partners's ALNY Position: Q2 2026 in Review

Evelyn Partners opened a new position in Alnylam Pharmaceuticals (ALNY) in Q2 2026: 175 shares worth $52.7K. The stake represents ﹤0.01% of the portfolio and ranks #366 among its holdings.

733 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Evelyn Partners held 175 shares of Alnylam Pharmaceuticals worth $52.7K as of Q2 2026.
  • Alnylam Pharmaceuticals was a new Evelyn Partners position in Q2 2026.
  • Alnylam Pharmaceuticals made up ﹤0.01% of Evelyn Partners's portfolio in Q2 2026, its #366 holding.
  • 733 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Evelyn Partners's 13F filing for Q2 2026, filed 7 Aug 2026.